Does a common sarcoidosis treatment raise lymphoma risk? new study investigates
NCT ID NCT07343401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study from Alexandria University looked at 40 adults with lung sarcoidosis who were receiving or about to start immunosuppressive therapy. Researchers tracked them for 12 months to see if any developed lymphoma, confirmed by lymph node biopsy. The goal was to understand whether this treatment might increase cancer risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this study finds a link, it could help doctors weigh the risks of immunosuppressive therapy in sarcoidosis patients.
- What could go wrong
- This is a small, completed observational study with only 40 participants. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alexandria main university hospital
Alexandria, Asafra, 11511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.